Related Experiment Video

Updated: May 11, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells

Hyunseung Lee1, Soo Jung Kim, Kyung Hee Jung

  • 1Department of Drug Development, College of Medicine, Inha University, Sinheung‑dong, Jung‑gu, Incheon 400-712, Republic of Korea.

Oncology Reports
|May 28, 2013
PubMed

Insights

A novel drug, HS-173, shows promise for treating non-small cell lung cancer (NSCLC). This phosphatidylinositol 3-kinase α (PI3Kα) inhibitor effectively reduced tumor cell proliferation and induced apoptosis in NSCLC cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality globally, representing 85% of lung cancer cases.
  • Epidermal growth factor receptor (EGFR) targeted therapies are common for NSCLC, but acquired resistance necessitates alternative treatment strategies.
  • The phosphatidylinositol 3-kinase (PI3K) signaling pathway is frequently dysregulated in various cancers, including NSCLC.

Purpose of the Study:

  • To investigate the anticancer effects of a novel phosphatidylinositol 3-kinase α (PI3Kα) inhibitor, HS-173, in human NSCLC cell lines.
  • To evaluate HS-173's impact on cancer cell proliferation, cell cycle progression, and apoptosis.
  • To determine if HS-173 effectively inhibits the PI3K signaling pathway.

Main Methods:

  • Treatment of human NSCLC cell lines with varying concentrations of HS-173.
  • Assessment of cell proliferation using standard assays.
  • Analysis of cell cycle distribution via flow cytometry.
  • Evaluation of apoptosis induction.
  • Western blot analysis to examine the phosphorylation status of key proteins in the PI3K/Akt/mTOR pathway.

Main Results:

  • HS-173 demonstrated significant anti-proliferative effects on NSCLC cells in a dose-dependent manner.
  • The compound effectively inhibited the PI3K signaling pathway, as evidenced by reduced downstream signaling.
  • HS-173 treatment led to cell cycle arrest at the G2/M phase and induced apoptosis in NSCLC cells.
  • Blocking the PI3K/Akt/mTOR pathway was identified as the mechanism underlying HS-173's anticancer activity.

Conclusions:

  • HS-173 exhibits potent anticancer activities against human NSCLC cell lines.
  • The novel PI3Kα inhibitor HS-173 induces apoptosis and cell cycle arrest by inhibiting the PI3K/Akt/mTOR pathway.
  • HS-173 represents a potential novel therapeutic agent for targeted NSCLC treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...